Results are summarized in Fig 5
Highest dose, obesity trial obesity-plus-diabetes trial (treatment-policy estimand): Semaglutide: 14.9% (STEP 1) 9.6% (STEP 2), a 5.3 point gap Tirzepatide: 20.9% (SURMOUNT-1) 14.7% (SURMOUNT-2), a 6.2 point gap Retatrutide: 25.0% (TRIUMPH-1) 20.8% (TRIUMPH-2 only efficacy-estimand currently reported so true gap is larger) It's still unclear the reason why we observe less weight loss in those with type 2 diabetes
It works by stimulating insulin secretion, suppressing glucagon secretion, slowing gastric emptying, and sending satiety signals to the brain
Our medical team ensures safe administration and personalized care throughout your treatment
They create multiple entry points based on the size and target area
Nissen, who serves as study co-chair of SURMOUNT-MMO, notes that the exclusion of patients with diabetes will avoid confounding of results by favorable outcomes due to tirzepatides antidiabetic effects